IL263223B2 - Antibodies against cd40 and their uses - Google Patents

Antibodies against cd40 and their uses

Info

Publication number
IL263223B2
IL263223B2 IL263223A IL26322318A IL263223B2 IL 263223 B2 IL263223 B2 IL 263223B2 IL 263223 A IL263223 A IL 263223A IL 26322318 A IL26322318 A IL 26322318A IL 263223 B2 IL263223 B2 IL 263223B2
Authority
IL
Israel
Prior art keywords
antibody
seq
antibodies
human
huab9
Prior art date
Application number
IL263223A
Other languages
English (en)
Hebrew (he)
Other versions
IL263223B (en
IL263223A (en
Inventor
Diane Hollenbaugh
Shiming Ye
Diane Sau Mun COHEN
Original Assignee
Abbvie Biotherapeutics Inc
Diane Hollenbaugh
Shiming Ye
Diane Sau Mun COHEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc, Diane Hollenbaugh, Shiming Ye, Diane Sau Mun COHEN filed Critical Abbvie Biotherapeutics Inc
Publication of IL263223A publication Critical patent/IL263223A/en
Publication of IL263223B publication Critical patent/IL263223B/en
Publication of IL263223B2 publication Critical patent/IL263223B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL263223A 2016-05-27 2017-05-26 Antibodies against cd40 and their uses IL263223B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662342417P 2016-05-27 2016-05-27
PCT/US2017/034681 WO2017205742A1 (en) 2016-05-27 2017-05-26 Anti-cd40 antibodies and their uses

Publications (3)

Publication Number Publication Date
IL263223A IL263223A (en) 2018-12-31
IL263223B IL263223B (en) 2022-11-01
IL263223B2 true IL263223B2 (en) 2023-03-01

Family

ID=59014833

Family Applications (1)

Application Number Title Priority Date Filing Date
IL263223A IL263223B2 (en) 2016-05-27 2017-05-26 Antibodies against cd40 and their uses

Country Status (35)

Country Link
US (8) US10519243B2 (enExample)
EP (2) EP3995511A1 (enExample)
JP (2) JP2019523221A (enExample)
KR (2) KR20220028143A (enExample)
CN (1) CN109476750B (enExample)
AR (2) AR108611A1 (enExample)
AU (1) AU2017271602A1 (enExample)
BR (1) BR112018074468A2 (enExample)
CA (1) CA3025347A1 (enExample)
CL (1) CL2018003366A1 (enExample)
CO (1) CO2018012699A2 (enExample)
CR (1) CR20180605A (enExample)
CY (1) CY1124806T1 (enExample)
DO (1) DOP2018000258A (enExample)
EC (1) ECSP18094829A (enExample)
ES (1) ES2901722T3 (enExample)
HR (1) HRP20211882T1 (enExample)
HU (1) HUE056670T2 (enExample)
IL (1) IL263223B2 (enExample)
LT (1) LT3464361T (enExample)
MX (1) MX393455B (enExample)
MY (1) MY195442A (enExample)
NZ (1) NZ748644A (enExample)
PE (1) PE20190970A1 (enExample)
PH (1) PH12018502456A1 (enExample)
PL (1) PL3464361T3 (enExample)
PT (1) PT3464361T (enExample)
RS (1) RS62726B1 (enExample)
RU (1) RU2752049C2 (enExample)
SG (2) SG11201810522UA (enExample)
SI (1) SI3464361T1 (enExample)
SM (1) SMT202100721T1 (enExample)
TW (2) TWI814279B (enExample)
UA (1) UA123111C2 (enExample)
WO (1) WO2017205742A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009059298A2 (en) * 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
SMT202100721T1 (it) 2016-05-27 2022-01-10 Abbvie Biotherapeutics Inc Anticorpi anti-cd40 e loro usi
CN112512572B (zh) * 2018-04-20 2024-12-10 礼进生物医药科技（上海）有限公司 抗cd40抗体及其用途
CA3119865A1 (en) 2018-11-23 2020-05-28 Strike Pharma Ab Bi-specific conjugates
MX2021005823A (es) * 2018-11-30 2021-07-15 Jiangsu Hengrui Medicine Co Anticuerpo anti-cd40, fragmento de union a antigeno y uso farmaceutico del mismo.
CN109912717B (zh) * 2019-03-04 2020-05-26 北京天广实生物技术股份有限公司 结合cd40的抗体及其用途
US10570210B1 (en) * 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
WO2020193718A1 (en) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Recombinant proteins with cd40 activating properties
AU2020256828A1 (en) * 2019-04-10 2021-11-18 Nankai University Anti-CD40 antibody and use thereof
GB201910900D0 (en) 2019-07-31 2019-09-11 Scancell Ltd Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
EP4027998A1 (en) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases
MX2022003009A (es) * 2019-09-11 2022-06-14 Novartis Ag Metodo para prevenir trastornos asociados a virus humanos en pacientes.
EP4048701A4 (en) * 2019-10-23 2024-05-29 Lyvgen Biopharma Holdings Limited Anti-cd40 binding molecules and bi-specific antibodies comprising such
CN115038718B (zh) * 2019-11-08 2024-07-02 山东先声生物制药有限公司 抗人程序性死亡配体-1（pd-l1）的抗体及其用途
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
EP4185320A4 (en) * 2020-07-23 2025-10-08 Dyne Therapeutics Inc MUSCLE TARGETING COMPLEXES AND THEIR USES IN THE TREATMENT OF MUSCLE ATROPHY
CN115403670B (zh) * 2021-05-26 2026-03-10 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
JP7881232B2 (ja) * 2022-05-31 2026-06-29 明済生物製薬（北京）有限公司 抗ｃｄ４０抗体と抗ｐｄ－ｌ１×ｃｄ４０二重特異性抗体及びその使用
CA3262796A1 (en) * 2022-09-20 2024-03-28 Currus Biologics Pty Ltd Bispecific Polypeptides and Their Uses
TW202500587A (zh) * 2023-02-16 2025-01-01 法商賽諾菲公司 Cd40結合蛋白

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707627A1 (en) * 2003-12-25 2006-10-04 Kirin Beer Kabushiki Kaisha Mutants of anti-cd40 antibody
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
US20140120103A1 (en) * 2012-10-30 2014-05-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
WO2014144960A2 (en) * 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Fc variants
WO2015091853A2 (en) * 2013-12-19 2015-06-25 Alligator Bioscience Ab Antibodies
EP2889377A1 (en) * 2012-08-24 2015-07-01 Chugai Seiyaku Kabushiki Kaisha Fc riib-specific fc region variant

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
MXPA02007473A (es) 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
JP2008505645A (ja) * 2004-07-10 2008-02-28 アレクシオン ファーマシューティカルズ， インコーポレイテッド ガン細胞に特異的な抗体を見出すための方法およびそれによって見出される抗体
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
US8323653B2 (en) * 2006-09-08 2012-12-04 Medimmune, Llc Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CA2701788C (en) * 2007-10-05 2017-06-13 Genentech, Inc. Humanized beta-amyloid antibody for treating ocular diseases
EP2796467B1 (en) * 2010-03-31 2018-03-28 Boehringer Ingelheim International GmbH Anti-CD40 antibodies
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
BR112017008959A2 (pt) 2014-10-29 2018-01-16 Seattle Genetics, Inc. método para tratamento de uma doença.
JP6518917B2 (ja) * 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用
SMT202100721T1 (it) * 2016-05-27 2022-01-10 Abbvie Biotherapeutics Inc Anticorpi anti-cd40 e loro usi
KR20190014525A (ko) * 2016-05-27 2019-02-12 애브비 바이오테라퓨틱스 인크. 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1707627A1 (en) * 2003-12-25 2006-10-04 Kirin Beer Kabushiki Kaisha Mutants of anti-cd40 antibody
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
EP2889377A1 (en) * 2012-08-24 2015-07-01 Chugai Seiyaku Kabushiki Kaisha Fc riib-specific fc region variant
US20140120103A1 (en) * 2012-10-30 2014-05-01 Apexigen, Inc. Anti-cd40 antibodies and methods of use
WO2014144960A2 (en) * 2013-03-15 2014-09-18 Abbvie Biotherapeutics Inc. Fc variants
WO2015091853A2 (en) * 2013-12-19 2015-06-25 Alligator Bioscience Ab Antibodies

Also Published As

Publication number Publication date
PE20190970A1 (es) 2019-07-09
PL3464361T3 (pl) 2022-01-31
SG11201810522UA (en) 2018-12-28
AR108611A1 (es) 2018-09-05
US20210024642A1 (en) 2021-01-28
US20210277137A1 (en) 2021-09-09
CO2018012699A2 (es) 2019-08-20
US20200010558A1 (en) 2020-01-09
US10400041B2 (en) 2019-09-03
KR20190014524A (ko) 2019-02-12
JP2022068294A (ja) 2022-05-09
CA3025347A1 (en) 2017-11-30
TWI761348B (zh) 2022-04-21
US20170342159A1 (en) 2017-11-30
HUE056670T2 (hu) 2022-02-28
EP3464361A1 (en) 2019-04-10
EP3464361B1 (en) 2021-11-10
WO2017205742A1 (en) 2017-11-30
IL263223B (en) 2022-11-01
TWI814279B (zh) 2023-09-01
MX393455B (es) 2025-03-24
US20220119542A1 (en) 2022-04-21
CN109476750B (zh) 2022-02-01
US20180186889A1 (en) 2018-07-05
RS62726B1 (sr) 2022-01-31
KR102366355B1 (ko) 2022-02-24
RU2018146533A3 (enExample) 2020-06-29
RU2018146533A (ru) 2020-06-29
SG10201914132RA (en) 2020-03-30
PH12018502456A1 (en) 2019-10-21
SI3464361T1 (sl) 2022-01-31
MY195442A (en) 2023-01-21
AR124692A2 (es) 2023-04-26
KR20220028143A (ko) 2022-03-08
JP7331179B2 (ja) 2023-08-22
SMT202100721T1 (it) 2022-01-10
RU2752049C2 (ru) 2021-07-22
CL2018003366A1 (es) 2019-03-15
LT3464361T (lt) 2022-01-10
US10597460B2 (en) 2020-03-24
EP3995511A1 (en) 2022-05-11
CN109476750A (zh) 2019-03-15
TW202229356A (zh) 2022-08-01
BR112018074468A2 (pt) 2019-03-06
PT3464361T (pt) 2021-12-27
ECSP18094829A (es) 2019-03-29
US20200040090A1 (en) 2020-02-06
DOP2018000258A (es) 2019-02-15
UA123111C2 (uk) 2021-02-17
HRP20211882T1 (hr) 2022-03-04
CY1124806T1 (el) 2022-11-25
AU2017271602A1 (en) 2018-12-13
NZ748644A (en) 2023-05-26
US10844131B2 (en) 2020-11-24
CR20180605A (es) 2020-01-13
US10023645B1 (en) 2018-07-17
US10519243B2 (en) 2019-12-31
ES2901722T3 (es) 2022-03-23
US20190071509A1 (en) 2019-03-07
TW201806971A (zh) 2018-03-01
IL263223A (en) 2018-12-31
JP2019523221A (ja) 2019-08-22
MX2018014630A (es) 2019-06-10

Similar Documents

Publication Publication Date Title
US10597460B2 (en) Anti-CD40 antibodies
JP7520072B2 (ja) Ｐｄ－ｌ１特異的抗体およびそれを使用する方法
US10875921B2 (en) Anti-4-1BB antibodies and their uses
IL264970B1 (en) ANTI-TIM-3 antibodies and their use
US20220372161A1 (en) Antibodies against the poliovirus receptor (pvr) and uses thereof
US20240309087A1 (en) Anti-cd112r antibody and use thereof
EP3902836B1 (en) Flt3 agonist antibodies and uses thereof
HK40006958B (en) Anti-cd40 antibodies and their uses
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение